Dave Greenwald, Ph.D., serves on the Board of Directors at Jaguar Gene Therapy, Axovia Therapeutics and Apertura Gene Therapy and is Vice President of Business Development on the therapeutics investment team at Deerfield Management. Since joining Deerfield in 2018, Dr. Greenwald has been responsible for searching for new investment opportunities, supporting business development of private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures and a co-founder and Chief Executive Officer of Relay Technology Management, Inc. Greenwald earned his B.S. in Cellular Biology & Molecular Genetics from University of Maryland, College Park and his Ph.D. in Genetics from Tufts University School of Medicine, where his doctoral thesis focused on gene therapy strategies to treat retinal degenerative diseases.
Gene therapy can offer hope to patients with previously untreatable diseases, but there’s more work to be done to improve both the safety and efficacy of this therapeutic modality.